The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes
- PMID: 22068611
- PMCID: PMC11114779
- DOI: 10.1007/s00018-011-0874-4
The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes
Abstract
Type-2 diabetes mellitus (T2DM) is a disorder that is characterized by high blood glucose concentration in the context of insulin resistance and/or relative insulin deficiency. It causes metabolic changes that lead to the damage and functional impairment of organs and tissues resulting in increased morbidity and mortality. It is this form of diabetes whose prevalence is increasing at an alarming rate due to the 'obesity epidemic', as obesity is a key risk factor in the development of insulin resistance. However, the majority of individuals who have insulin resistance do not develop diabetes due to a compensatory increase in insulin secretion in response to an increase in insulin demand. This adaptive response is sustained by an increase in both β-cell function and mass. Importantly, there is increasing evidence that the Serine/Threonine kinase mammalian target of rapamycin (mTOR) plays a key role in the regulation of β-cell mass and therefore likely plays a critical role in β-cell adaptation. Therefore, the primary focus of this review is to summarize our current understanding of the role of mTOR in stimulating pancreatic β-cell mass and thus, in the prevention of type-2 diabetes.
Figures



Similar articles
-
Role of the mammalian target of rapamycin (mTOR) complexes in pancreatic β-cell mass regulation.Vitam Horm. 2014;95:425-69. doi: 10.1016/B978-0-12-800174-5.00017-X. Vitam Horm. 2014. PMID: 24559928 Review.
-
PKCζ Is Essential for Pancreatic β-Cell Replication During Insulin Resistance by Regulating mTOR and Cyclin-D2.Diabetes. 2016 May;65(5):1283-96. doi: 10.2337/db15-1398. Epub 2016 Feb 11. Diabetes. 2016. PMID: 26868297 Free PMC article.
-
Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.Front Endocrinol (Lausanne). 2022 Mar 31;13:869414. doi: 10.3389/fendo.2022.869414. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35432205 Free PMC article. Review.
-
mTOR: A double-edged sword for diabetes.J Leukoc Biol. 2019 Aug;106(2):385-395. doi: 10.1002/JLB.3MR0317-095RR. Epub 2018 Mar 26. J Leukoc Biol. 2019. PMID: 29578634 Review.
-
Role of natural mTOR inhibitors in treatment of diabetes mellitus.Fundam Clin Pharmacol. 2023 Jun;37(3):461-479. doi: 10.1111/fcp.12851. Epub 2022 Dec 20. Fundam Clin Pharmacol. 2023. PMID: 36415968 Review.
Cited by
-
The burden of cancer in metabolic dysfunction-associated steatotic liver disease.Rom J Morphol Embryol. 2024 Oct-Dec;65(4):627-635. doi: 10.47162/RJME.65.4.09. Rom J Morphol Embryol. 2024. PMID: 39957024 Free PMC article. Review.
-
Plasma Branched-Chain Amino Acids Are Associated With Greater Fasting and Postprandial Insulin Secretion in Non-diabetic Chinese Adults.Front Nutr. 2021 Apr 28;8:664939. doi: 10.3389/fnut.2021.664939. eCollection 2021. Front Nutr. 2021. PMID: 33996878 Free PMC article.
-
Roles of mTOR in the Regulation of Pancreatic β-Cell Mass and Insulin Secretion.Biomolecules. 2022 Apr 21;12(5):614. doi: 10.3390/biom12050614. Biomolecules. 2022. PMID: 35625542 Free PMC article. Review.
-
Role of microRNAs in islet beta-cell compensation and failure during diabetes.J Diabetes Res. 2014;2014:618652. doi: 10.1155/2014/618652. Epub 2014 Mar 5. J Diabetes Res. 2014. PMID: 24734255 Free PMC article. Review.
-
mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis.PLoS One. 2015 Sep 18;10(9):e0138625. doi: 10.1371/journal.pone.0138625. eCollection 2015. PLoS One. 2015. PMID: 26382847 Free PMC article.
References
-
- Ackermann AM, Gannon M. Molecular regulation of pancreatic beta-cell mass development, maintenance, and expansion. J Mol Endocrinol. 2007;38:193–206. - PubMed
-
- Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7:261–269. - PubMed
-
- Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, Jiang Y. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science. 2007;318:977–980. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous